Alida Bio
San Diego, US · Founded 2020 · 3 known investors
Alida Biosciences develops EpiPlex, a platform for detecting RNA modifications (m6A, inosine, and pseudouridine) through both turnkey profiling services and in-lab kits, with EpiScout machine-learning software that converts sequencing data into analysis results. It serves researchers in epitranscriptomics and supports real-world sample types such as FFPE, liquid biopsy, and RNA-limited inputs.
Founders & leadership
Investors · 3
Reported raises · per SEC filings
Form D private placements$12M disclosed across 3 rounds · 2021–2024
▶$7.5MraisedJun 2024 · 3 investors · BiotechnologyRule 506(b)
- Landon MerrillDirector
- Gudrun StengelExecutive Officer, Director
- Paul ConleyDirector
- John DrewryDirector
- Offering amount
- $8.5M
- Amount sold
- $7.5M
- First sale
- Jun 2024
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$4MraisedMay 2022 · 2 investors · BiotechnologyRule 506(b)
- John DrewryDirector
- Gudrun StengelExecutive Officer, Director
- Paul ConleyDirector
- Offering amount
- $4M
- Amount sold
- $4M
- First sale
- May 2022
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$510KraisedJul 2021 · 4 investors · BiotechnologyRule 506(b)
- John DrewryDirector
- Gudrun StengelExecutive Officer, Director
- Offering amount
- $1.1M
- Amount sold
- $510K
- First sale
- Jun 2021
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 6 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2023 | $1.1M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2023 | $865.2K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2023 | $347.7K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2022 | $259.6K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2022 | $259.5K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2021 | $255K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Alida Bio do?
- Alida Biosciences develops EpiPlex, a platform for detecting RNA modifications (m6A, inosine, and pseudouridine) through both turnkey profiling services and in-lab kits, with EpiScout machine-learning software that converts sequencing data into analysis results. It serves researchers in epitranscriptomics and supports real-world sample types such as FFPE, liquid biopsy, and RNA-limited inputs.
- Who are Alida Bio's investors?
- Alida Bio's investors include FusionX Ventures, GENERAL INCEPTION, Vertical Venture Partners.
- How much funding has Alida Bio raised?
- Alida Bio has disclosed $12M raised across 3 rounds.
- Where is Alida Bio headquartered?
- Alida Bio is headquartered in San Diego, US.